- Home
- PHUN vs HURA Comparison
PHUN vs HURA Comparison
Compare PHUN & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PHUN | HURA |
|---|---|---|
| Founded | 2009 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.0M | 35.5M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | PHUN | HURA |
|---|---|---|
| Price | $1.66 | $1.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $7.25 | ★ $10.00 |
| AVG Volume (30 Days) | 209.6K | ★ 3.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,883,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $95.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.57 | N/A |
| 52 Week Low | $1.56 | $0.41 |
| 52 Week High | $3.88 | $4.41 |
Technical Indicators
Market Signals| Indicator | PHUN | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 39.38 | 65.24 |
| Support Level | $1.56 | $0.70 |
| Resistance Level | $2.04 | $1.55 |
| Average True Range (ATR) | 0.12 | 0.22 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 23.08 | 73.25 |
Price Performance
Historical ComparisonAbout PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.